Adult onset Niemann-Pick type C: 24 month follow-up on miglustat
Objective: To present a rare case of adult onset NPC patient and pointing out varying response of her distinct symptoms on long term follow up…Amelioration of αLPHA-synuclein aggregation and motor behavior deficits by apocyanin in intranigral lipopolysaccharide induced animal model of Parkinson’s disease
Objective: The present study evaluated the therapeutic potentials of apocyanin for the treatment of neurobehavioral consequences in LPS induced PD model. Background: Parkinson's disease (PD),…May early introduction of dopaminergic agonists improve simptoms after ischemic stroke? The interim report
Objective: To evaluate the effect of bromocriptine on motor impairment, functional disabilit and cognitive impairment 5, 10, and 15 of bromocriptine therapy in patients with…Creativity related to dopaminergic treatment. A multicenter study
Objective: To study patients with Parkinson´s disease (PD) and enhanced creativity related to dopaminergic therapy. Background: Impulse control disorders (ICD) including pathological gambling, hypersexuality, and…Levodopa-carbidopa intestinal gel via PEG-J for advanced Parkinson’s disease- A single centre experience
Objective: To investigate clinical outcome and possible complications of LCIG in patients with advanced PD in years 2006-2014 at Helsinki University Hospital. Background: Continuous levodopa-carbidopa…Telemedicine facilitates efficient and safe home titration of levodopa/carbidopa intestinal gel (LCIG) in patients with advanced Parkinson’s disease
Objective: To demonstrate feasibility of TM for LCIG home titration, evaluate resource use, and assess patient, neurologist and nurse satisfaction. Background: LCIG, is used for…Oligomeric and phosphorylated alpha-synuclein as potential CSF biomarkers for Parkinson’s disease
Objective: To explore the potential use of alpha-synuclein (α-syn) species as candidate biomarkers for Parkinson's disease (PD). Background: Despite decades of intensive research, to date,…Day case initiation of subcutaneous apomorphine in people with Parkinson’s disease: A retrospective analysis from a UK teaching hospital
Objective: To evaluate a cohort of people with Parkinson's disease (PD) who were initiated on subcutaneous apomorphine injections or continuous subcutaneous apomorphine infusions (CSAI) on…Opicapone in fluctuating Parkinson’s disease patients: OFF- and ON-time responder post-hoc analyses of pooled phase III studies
Objective: Evaluate the proportion of patients with Parkinson's disease and motor fluctuations responding to opicapone (OPC) or placebo treatment over a 14-15 week treatment period.…A randomized controlled clinical study to evaluate efficacy, safety and tolerability of SC L-dopa/carbidopa (ND0612H) infusion regimens in fluctuating PD patients
Objective: To evaluate the efficacy, safety & tolerability of continuous subcutaneous infusion regimens of ND0612H. Background: L-dopa remains the most effective PD medication, however oral…
- « Previous Page
- 1
- …
- 62
- 63
- 64
- 65
- 66
- …
- 207
- Next Page »